An Open Label, Single Arm, Prospective Phase II Study to Evaluate the Efficacy and Safety of Bevacizumab with Gemcitabine and Carboplatin As First-Line Treatment for Metastatic Triple Negative Breast Cancer Patients.

Sudeep Gupta,Govind K. Babu,Raju Titus Chacko,Dinesh Doval,Chirag Desai,Nalini Kilara,Shona Milon Nag,Chirag A. Shah,S. V. S. Deo,Smruti B. Koppikar,Binay Swarup,Anil Arjundas Kukreja,Vinod Raina

Journal of clinical oncology（2018）

引用 0|浏览26

暂无评分

摘要

1098Background: There is a higher burden (29.2%-46%) of TNBC patients in India. This single arm, phase II trial evaluated the efficacy and safety of bevacizumab in combination with gemcitabine and ...

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要